Cited by 1,557Lipoproteins and Cardiovascular HealthCancer, Lipids, and MetabolismAcute Myocardial Infarction Research

The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.

Measurement of C-Reactive Protein for the Targeting of Statin Therapy in the Primary Prevention of Acute Coronary Events

Open access

Ridker, Paul M., Rifai, Nader, Clearfield, Michael, Downs, John R., Weis, Stephen E., Miles, J. Shawn, Gotto, Antonio M.·2001·New England Journal of Medicine

DOI 10.1056/nejm200106283442601

Open this paper in CoChat — free account Open PDF

Abstract

BACKGROUND: Elevated levels of C-reactive protein, even in the absence of hyperlipidemia, are associated with an increased risk of coronary events. Statin therapy reduces the level of C-reactive protein independently of its effect on lipid levels. We hypothesized that statins might prevent coronary events in persons with elevated C-reactive protein levels who did not have overt hyperlipidemia. METHODS: The level of C-reactive protein was measured at base line and after one year in 5742 participants in a five-year randomized trial of lovastatin for the primary prevention of acute coronary events. RESULTS: The rates of coronary events increased significantly with increases in the base-line levels of C-reactive protein. Lovastatin therapy reduced the C-reactive protein level by 14.8 percent (P<0.001), an effect not explained by lovastatin-induced changes in the lipid profile. As expected, lovastatin was effective in preventing coronary events in participants whose base-line ratio of total cholesterol to high-density lipoprotein (HDL) cholesterol was higher than the median ratio, regardless of the level of C-reactive protein (number needed to treat for five years to prevent 1 event, 47; P=0.005). However, lovastatin was also effective among those with a ratio of total to HDL cholesterol that was lower than the median and a C-reactive protein level higher than the median (number needed to treat, 43; P=0.02). In contrast, lovastatin was ineffective among participants with a ratio of total to HDL cholesterol and a C-reactive protein level that were both lower than the median (number needed to treat, 983; P=0.80). CONCLUSIONS: Statin therapy may be effective in the primary prevention of coronary events among subjects with relatively low lipid levels but with elevated levels of C-reactive protein.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1056/nejm200106283442601

Cites

28 of 28 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II)
Grundy, S. M., Bilheimer, D. W., Chait, A., Clark, L. T., Denke, M. A., Havel, R. J., Hazzard, W. R., Hulley, S. B., Hunninghake, D. B., Kreisberg, R. A., et al. (1993) · JAMA · doi:10.1001/jama.269.23.3015 · Cited by 27,944
Atherosclerosis--an inflammatory disease
Ross, R. (1999) · New England Journal of Medicine · doi:10.1056/nejm199901143400207 · Cited by 21,725
Prevention of Coronary Heart Disease with Pravastatin in Men with Hypercholesterolemia
Shepherd, J., Cobbe, S. M., Ford, I., Isles, C. G., Lorimer, A. R., Macfarlane, P. W., McKillop, J. H., & Packard, C. J. (1995) · New England Journal of Medicine · doi:10.1056/nejm199511163332001 · Cited by 7,449
C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women
Ridker, P. M., Hennekens, C. H., Buring, J. E., & Rifai, N. (2000) · New England Journal of Medicine · doi:10.1056/nejm200003233421202 · Cited by 5,850
Self-citation
Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men
Ridker, P. M., Cushman, M., Stampfer, M. J., Tracy, R. P., & Hennekens, C. H. (1997) · New England Journal of Medicine · doi:10.1056/nejm199704033361401 · Cited by 5,504
Self-citation
Primary Prevention of Acute Coronary Events With Lovastatin in Men and Women With Average Cholesterol Levels: Results of AFCAPS/TexCAPS
Downs, J. R., Clearfield, M., Weis, S., Whitney, E., Shapiro, D. R., Beere, P. A., Langendorfer, A., Stein, E. A., Kruyer, W., Gotto, Jr., et al. (1998) · JAMA · doi:10.1001/jama.279.20.1615 · Cited by 5,236
Self-citation
PREVENTION OF CORONARY HEART DISEASE WITH PRAVASTATIN IN MEN WITH HYPERCHOLESTEROLEMIA
Hepherd, J. A. S., Obbe, S. T. M. C., Ord, I. A. F., Sles, C. H. G. I., Orimer, A. R. O. L., Acfarlane, P. E. W. M., Illop, J. A. H. M. C. K., Ackard, C. H. J. P., & Roup, S. T. G. (1995) · Cited by 3,453
Elevated C-reactive protein levels in overweight and obese adults
Visser, M. (1999) · JAMA · doi:10.1001/jama.282.22.2131 · Cited by 2,494
Molecular Bases of the Acute Coronary Syndromes
Libby, P. (1995) · Circulation · doi:10.1161/01.cir.91.11.2844 · Cited by 2,029
C-Reactive Protein, a Sensitive Marker of Inflammation, Predicts Future Risk of Coronary Heart Disease in Initially Healthy Middle-Aged Men
Köenig, W., Sund, M., Fröhlich, M., Fischer, H.-G., Löwel, H., Döring, A., Hutchinson, W. L., & Pepys, M. B. (1999) · Circulation · doi:10.1161/01.cir.99.2.237 · Cited by 1,952

Show all 27 references

Sorted by citations

Items 101–200 of 998

C-reactive protein and the biology of disease
Ansar, W., & Ghosh, S. (2013) · Immunologic Research · doi:10.1007/s12026-013-8384-0 · Cited by 350
High coronary artery calcium scores pose an extremely elevated risk for hard events
Wayhs, R., Zelinger, A. B., & Raggi, P. (2002) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(01)01737-5 · Cited by 336
C-Reactive Protein and Other Emerging Blood Biomarkers to Optimize Risk Stratification of Vulnerable Patients
Tsimikas, S., Willerson, J. T., & Ridker, P. M. (2006) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2005.10.066 · Cited by 332
Self-citation
C-Reactive Protein and Cerebral Small-Vessel Disease
van Dijk, E. J., Prins, N. D., Vermeer, S. E., Vrooman, H. A., Albert Hofman, D., Koudstaal, P. J., & Breteler, M. M. B. (2005) · Circulation · doi:10.1161/circulationaha.104.506337 · Cited by 327
Effect of Statin Therapy on the Risk for Incident Heart Failure in Patients With Breast Cancer Receiving Anthracycline Chemotherapy
Seicean, S., Seicean, A., Plana, J. C., Budd, G. T., & Marwick, T. H. (2012) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.07.067 · Cited by 325
High-sensitivity C-reactive protein and atherosclerotic disease: from improved risk prediction to risk-guided therapy
Koenig, W. (2013) · International Journal of Cardiology · doi:10.1016/j.ijcard.2013.07.113 · Cited by 315
Cholesterol-lowering efficacy of a microencapsulated bile salt hydrolase-activeLactobacillus reuteriNCIMB 30242 yoghurt formulation in hypercholesterolaemic adults
Jones, M. L., Martoni, C., Parent, M., & Prakash, S. (2011) · British Journal Of Nutrition · doi:10.1017/s0007114511004703 · Cited by 331
Assessment and Treatment of Cardiovascular Risk in Prediabetes: Impaired Glucose Tolerance and Impaired Fasting Glucose
DeFronzo, R. A., & Abdul‐Ghani, M. A. (2011) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2011.03.013 · Cited by 324
Elevated Serum C-Reactive Protein Levels and Early Arterial Changes in Healthy Children
Järvisalo, M. J., Harmoinen, A. P. T., Hakanen, M., Paakkunainen, U., Viikari, J. S. A., Hartiala, J., Lehtimäki, T. J., Simell, O., & Raitakari, O. T. (2002) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.0000024222.06463.21 · Cited by 317
Kidney physiology and susceptibility to acute kidney injury: implications for renoprotection
Scholz, H., Boivin, F. J., Schmidt-Ott, K. M., Bachmann, S., Eckardt, K., Scholl, U. I., & Persson, P. B. (2021) · Nature Reviews Nephrology · doi:10.1038/s41581-021-00394-7 · Cited by 328
Clinical practice guidelines for managing dyslipidemias in kidney transplant patients: a report from the Managing Dyslipidemias in Chronic Kidney Disease Work Group of the National Kidney Foundation Kidney Disease Outcomes Quality Initiative
Kasiske, B. L., Cosío, B. G., Beto, J. A., Bolton, K., Chavers, B. M., Grimm, R. H., Levin, A., Masri, B. A., Parekh, R. S., Wanner, C., et al. (2004) · American Journal of Transplantation · doi:10.1111/j.1600-6135.2004.0355.x · Cited by 313
Obesity and Cardiovascular Disease: a Risk Factor or a Risk Marker?
Mandviwala, T., Khalid, U., & Deswal, A. M. (2016) · Current Atherosclerosis Reports · doi:10.1007/s11883-016-0575-4 · Cited by 329
Anti-inflammatory therapeutics for the treatment of atherosclerosis
Charo, I. F., & Taub, R. A. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3444 · Cited by 314
Residual inflammatory risk: addressing the obverse side of the atherosclerosis prevention coin
Ridker, P. M. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw024 · Cited by 316
Self-citation
Clinical Relevance of C-Reactive Protein During Follow-Up of Patients With Acute Coronary Syndromes in the Aggrastat-to-Zocor Trial
Morrow, D. A., de Lemos, J. A., Sabatine, M. S., Wiviott, S. D., Blazing, M. A., Shui, A. M., Rifai, N., Califf, R. M., & Braunwald, E. (2006) · Circulation · doi:10.1161/circulationaha.106.628909 · Cited by 305
Self-citation
Atherosclerotic cardiovascular disease risk assessment: An American Society for Preventive Cardiology clinical practice statement
Wong, N. D., Budoff, M. J., Ferdinand, K. C., Graham, I. M., Michos, E. D., Reddy, T. K., Shapiro, M. D., & Toth, P. P. (2022) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2022.100335 · Cited by 327
Statins for the primary prevention of cardiovascular disease
Taylor, F. C., Ward, K. J., Moore, T. H., Burke, M., Smith, G. D., Casas, J. P., & Ebrahim, S. B. J. (2011) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004816.pub4 · Cited by 315
Effects of Statins on 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibition Beyond Low-Density Lipoprotein Cholesterol
Liao, J. K. (2005) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2005.06.009 · Cited by 310
Effect of Pravastatin on Loss of Renal Function in People with Moderate Chronic Renal Insufficiency and Cardiovascular Disease
Tonelli, M. A., Moyé, L. A., Sacks, F. M., Cole, T., & Curhan, G. C. (2003) · Journal of the American Society of Nephrology · doi:10.1097/01.asn.0000068461.45784.2f · Cited by 299
Targeting Interleukin-1 in Heart Disease
Tassell, B. W. V., Toldo, S. A., Mezzaroma, E., & Abbate, A. (2013) · Circulation · doi:10.1161/circulationaha.113.003199 · Cited by 321
High-sensitivity C-reactive protein is an independent clinical feature of nonalcoholic steatohepatitis (NASH) and also of the severity of fibrosis in NASH
Yoneda, M., Mawatari, H., Fujita, K., Iida, H., Yonemitsu, K., Kato, S., Takahashi, H., Kirikoshi, H., Inamori, M., Nozaki, Y., et al. (2007) · Journal of Gastroenterology · doi:10.1007/s00535-007-2060-x · Cited by 294
High-sensitivity C-reactive protein, inflammation, and cardiovascular risk: From concept to clinical practice to clinical benefit
Ridker, P. M. (2004) · American Heart Journal · doi:10.1016/j.ahj.2004.04.028 · Cited by 290
Self-citation
Evaluation of C-Reactive Protein Measurement for Assessing the Risk and Prognosis in Ischemic Stroke
Napoli, M. D., Schwaninger, M., Cappelli, R., Ceccarelli, E., Gianfilippo, G. D., Donati, C., Emsley, H. C. A., Forconi, S., Hopkins, S. J., Masotti, L., et al. (2005) · Stroke · doi:10.1161/01.str.0000165929.78756.ed · Cited by 290
Treatment of Relapsing Paralysis in Experimental Encephalomyelitis by Targeting Th1 Cells through Atorvastatin
Aktaş, O., Waiczies, S., Тихоновна, С. А., Dörr, J. R., Seeger, B., Prozorovski, T., Sallach, S., Endres, M., Brocke, S., Nitsch, R., et al. (2003) · The Journal of Experimental Medicine · doi:10.1084/jem.20021425 · Cited by 280
The incidence and risk factors of cholesterol embolization syndrome, a complication of cardiac catheterization: a prospective study
Fukumoto, Y., Tsutsui, H., Tsuchihashi, M., Masumoto, A., & Takeshita, A. (2003) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(03)00579-5 · Cited by 277
Evaluation of Biomarkers and Surrogate Endpoints in Chronic Disease
Institute of Medicine (2010) · National Academies Press eBooks · doi:10.17226/12869 · Cited by 274
The Role of Nutraceuticals in Statin Intolerant Patients
Banach, M., Patti, A. M., Giglio, R. V., Cicero, A. F. G., Atanasov, A. G., Bajraktari, G., Bruckert, E., Descamps, O., Djuric, D. M., Ezhov, M., et al. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.04.040 · Cited by 272
Residual Inflammatory Risk on Treatment With PCSK9 Inhibition and Statin Therapy
Pradhan, A. D., Aday, A. W., Rose, L. M., & Ridker, P. M. (2018) · Circulation · doi:10.1161/circulationaha.118.034645 · Cited by 258
Self-citation
European guidelines on cardiovascular disease prevention in clinical practice Third Joint Task Force of European and other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of eight societies and by invited experts)
Backer, G. D., Ambrosioni, E., Broch-Johnsen, K., Brotons, C., Cífková, R., Dallongeville, J., Ebrahim, S. B. J., Færgeman, O., Graham, I. D., Mancia, G., et al. (2003) · European Journal of Cardiovascular Prevention & Rehabilitation · doi:10.1097/00149831-200312001-00001 · Cited by 273
Congestive Heart Failure in Renal Transplant Recipients
Rigatto, C., Parfrey, P. S., Foley, R. N., Negrijn, C., Tribula, C., & Jeffery, J. (2002) · Journal of the American Society of Nephrology · doi:10.1681/asn.v1341084 · Cited by 273
Narrative Review: Assessment of C-Reactive Protein in Risk Prediction for Cardiovascular Disease
Lloyd‐Jones, D. M., Liu, K., Tian, L., & Greenland, P. (2006) · Annals of Internal Medicine · doi:10.7326/0003-4819-145-1-200607040-00129 · Cited by 272
Testing the inflammatory hypothesis of atherothrombosis: scientific rationale for the cardiovascular inflammation reduction trial (CIRT)
Ridker, P. M. (2009) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2009.03404.x · Cited by 269
Self-citation
Plasma Concentration of C-Reactive Protein and the Calculated Framingham Coronary Heart Disease Risk Score
Albert, M. A., Glynn, R. J., & Ridker, P. M. (2003) · Circulation · doi:10.1161/01.cir.0000080289.72166.cf · Cited by 267
Self-citation
Clinical utility of inflammatory markers and advanced lipoprotein testing: Advice from an expert panel of lipid specialists
Davidson, M. H., Ballantyne, C. M., Jacobson, T. A., Bittner, V. A., Braun, L. T., Brown, A. S., Brown, W. V., Cromwell, W. C., Goldberg, R. B., McKenney, J. M., et al. (2011) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2011.07.005 · Cited by 262
The HMG-CoA reductase inhibitor atorvastatin prevents atrial fibrillation by inhibiting inflammation in a canine sterile pericarditis model
Kumagai, K. (2004) · Cardiovascular Research · doi:10.1016/j.cardiores.2004.01.018 · Cited by 267
High-sensitivity C-reactive protein and cardiovascular risk: rationale for screening and primary prevention
Ridker, P. M. (2003) · The American Journal of Cardiology · doi:10.1016/s0002-9149(03)00774-4 · Cited by 261
Self-citation
Anticytokine Agents: Targeting Interleukin Signaling Pathways for the Treatment of Atherothrombosis
Ridker, P. M. (2019) · Circulation Research · doi:10.1161/circresaha.118.313129 · Cited by 260
Self-citation
One-Year Consumption of a Grape Nutraceutical Containing Resveratrol Improves the Inflammatory and Fibrinolytic Status of Patients in Primary Prevention of Cardiovascular Disease
Tomé‐Carneiro, J., Gonzálvez, M., Larrosa, M., Yáñez-Gascón, M. J., García‐Almagro, F. J., Ruiz‐Ros, J. A., García‐Conesa, M., Tomás-Barberán, F. A., & Espı́n, J. C. (2012) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2012.03.030 · Cited by 260
Behavioural treatments for chronic systemic inflammation: effects of dietary weight loss and exercise training
Nicklas, B. J. (2005) · Canadian Medical Association Journal · doi:10.1503/cmaj.1040769 · Cited by 259
Primary prevention of coronary heart disease: integration of new data, evolving views, revised goals, and role of rosuvastatin in management. A comprehensive survey
KONES, R. J. (2011) · Drug Design Development and Therapy · doi:10.2147/dddt.s14934 · Cited by 266
Endothelial function, inflammation, and prognosis in cardiovascular disease
Gonzalez, M. A., & Selwyn, A. P. (2003) · The American Journal of Medicine · doi:10.1016/j.amjmed.2003.09.016 · Cited by 263
Concentration in plasma of macrophage inhibitory cytokine-1 and risk of cardiovascular events in women: a nested case-control study
Brown, D. A., Breit, S. N., Buring, J. E., Fairlie, W. D., Bauskin, A. R., Liu, T., & Ridker, P. M. (2002) · The Lancet · doi:10.1016/s0140-6736(02)09093-1 · Cited by 261
Self-citation
Relation of C-Reactive Protein to Abdominal Adiposity
Brooks, G. C., Blaha, M. J., & Blumenthal, R. S. (2010) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2010.02.017 · Cited by 255
Triglycerides and residual atherosclerotic risk
Raposeiras-Roubin, S., Rosselló, X., Oliva, B., Fernández-Friera, L., Mendiguren, J. M., Andrés, V., Bueno, H., Sanz, J., Martínez de Vega, V., Abu-Assi, E., et al. (2021) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.04.059 · Cited by 254
Usefulness of Red Cell Distribution Width as a Prognostic Marker in Pulmonary Hypertension††Conflicts of interest: Dr. Gomberg-Maitland has received research grant support from Actelion Pharmaceuticals Ltd., Allschwil, Switzerland; CoTherix, Inc., South San Francisco, California; Encysive Pharmaceuticals Inc., Houston, Texas; Gilead Sciences Inc., Foster City, California; Eli Lilly/ICOS, Indianapolis, Indiana; Pfizer Inc., New York, New York; and United Therapeutics, Silver Spring, Maryland. Dr. Gomberg-Maitland has served as a consultant and/or on advisory boards for Encysive Pharmaceuticals Inc., Gilead Sciences Inc., Pfizer Inc., and United Therapeutics. Dr. Shah has received research grant support from Actelion Pharmaceuticals Ltd. (Entelligence Young Investigator Award) and is also the recipient of a Scientist Development Grant from the American Heart Association, Dallas, Texas.
Hampole, C. V., Mehrotra, A. K., Thenappan, T., Gomberg‐Maitland, M., & Shah, S. J. (2009) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2009.05.016 · Cited by 255
Cardiac biomarkers and the case for point-of-care testing
McDonnell, B., Hearty, S., Leonard, P., & O’Kennedy, R. J. (2009) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2009.01.019 · Cited by 257
Hyperglycemia-induced Production of Acute Phase Reactants in Adipose Tissue
Lin, Y., Rajala, M. W., Berger, J. P., Moller, D. E., Barzilai, N., & Scherer, P. E. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m107101200 · Cited by 255
Genotype at a promoter polymorphism of the interleukin-6 gene is associated with baseline levels of plasma C-reactive protein
Vickers, M. A. (2002) · Cardiovascular Research · doi:10.1016/s0008-6363(01)00534-x · Cited by 249
C-reactive protein and cardiovascular disease: new insights from an old molecule
Hirschfield, G. M., & Pepys, M. B. (2003) · QJM · doi:10.1093/qjmed/hcg134 · Cited by 256
First-Trimester C-Reactive Protein and Subsequent Gestational Diabetes
Wolf, M. S., Sandler, L., Hsu, K., Smirnakis, K. V., Ecker, J. L., & Thadhani, R. (2003) · Diabetes Care · doi:10.2337/diacare.26.3.819 · Cited by 256
Long-Term Effects of a High-Protein, Low-Carbohydrate Diet on Weight Control and Cardiovascular Risk Markers in Obese Hyperinsulinemic Subjects
Brinkworth, G. D., Noakes, M., Keogh, J. B., Luscombe, N. D., Wittert, G. A., & Clifton, P. M. (2004) · International Journal of Obesity · doi:10.1038/sj.ijo.0802617 · Cited by 245
Physical Activity and High-Sensitivity C-Reactive Protein
Plaisance, E. P., & Grandjean, P. W. (2006) · Sports Medicine · doi:10.2165/00007256-200636050-00006 · Cited by 246
Preanalytic and Analytic Sources of Variations in C-reactive Protein Measurement: Implications for Cardiovascular Disease Risk Assessment
Ledue, T. B., & Rifai, N. (2003) · Clinical Chemistry · doi:10.1373/49.8.1258 · Cited by 238
Self-citation
Coronary heart disease risk: Low-density lipoprotein and beyond
Shaya, G. E., Leucker, T. M., Jones, S. R., Martin, S. S., & Toth, P. P. (2021) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2021.04.002 · Cited by 247
Ezetimibe and Simvastatin Reduce Inflammation, Disease Activity, and Aortic Stiffness and Improve Endothelial Function in Rheumatoid Arthritis
Maki-Petaja, K. M., Booth, A. D., Hall, F. C., Wallace, S. M. L., Brown, J., McEniery, C. M., & Wilkinson, I. B. (2007) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2007.04.076 · Cited by 241
Association of C-Reactive Protein With Carotid Atherosclerosis in Men and Women: The Framingham Heart Study
Wang, T. J., Nam, B., Wilson, P. W. F., Wolf, P. A., Levy, D. A., Polak, J. F., D’Agostino, R. B., & O’Donnell, C. J. (2002) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.0000034543.78801.69 · Cited by 236
Lupus Atherosclerosis Prevention Study (LAPS)
Petri, M. A., Kiani, A. N., Post, W. S., Christopher‐Stine, L., & Magder, L. S. (2010) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2010.136762 · Cited by 240
Relative Efficacy of Atorvastatin 80 mg and Pravastatin 40 mg in Achieving the Dual Goals of Low-Density Lipoprotein Cholesterol <70 mg/dl and C-Reactive Protein <2 mg/l
Ridker, P. M., Morrow, D. A., Rose, L. M., Rifai, N., Cannon, C. P., & Braunwald, E. (2005) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2005.02.080 · Cited by 236
Self-citation
C-reactive protein is associated with renal function abnormalities in a non-diabetic population
Stuveling, E. M., Hillege, H. L., Bakker, S. J. L., Gans, R. O. B., de Jong, P. E., & de Zeeuw, D. (2003) · Kidney International · doi:10.1046/j.1523-1755.2003.00762.x · Cited by 232
C-reactive protein is a mediator of cardiovascular disease
Bisoendial, R. J., Boekholdt, S. M., Vergeer, M., Stroes, E. S. G., & Kastelein, J. J. P. (2010) · European Heart Journal · doi:10.1093/eurheartj/ehq238 · Cited by 230
The Metabolic Syndrome and Inflammation
Sutherland, J. P., McKinley, B., & Eckel, R. H. (2004) · Metabolic Syndrome and Related Disorders · doi:10.1089/met.2004.2.82 · Cited by 243
Mechanisms of plaque stabilization with statins
Libby, P., & Aikawa, M. (2003) · The American Journal of Cardiology · doi:10.1016/s0002-9149(02)03267-8 · Cited by 228
Nuclear factor κB: a potential therapeutic target in atherosclerosis and thrombosis
Monaco, C. G. (2004) · Cardiovascular Research · doi:10.1016/j.cardiores.2003.11.038 · Cited by 227
C-reactive protein and incident coronary heart disease in the Atherosclerosis Risk In Communities (ARIC) study
Folsom, A. R., Aleksic, N., Catellier, D., Juneja, H. S., & Wu, K. K. (2002) · American Heart Journal · doi:10.1067/mhj.2002.124054 · Cited by 227
Inflammatory markers and cardiovascular health in older adults
Kritchevsky, S. B., Cesari, M., & Pahor, M. (2005) · Cardiovascular Research · doi:10.1016/j.cardiores.2004.12.026 · Cited by 222
From Lipids to Inflammation: New Approaches to Reducing Atherosclerotic Risk
Shapiro, M. D., & Fazio, S. (2016) · Circulation Research · doi:10.1161/circresaha.115.306471 · Cited by 217
Efficacy of Rosuvastatin Among Men and Women With Moderate Chronic Kidney Disease and Elevated High-Sensitivity C-Reactive Protein
Ridker, P. M., MacFadyen, J. G., Cressman, M. D., & Glynn, R. J. (2010) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2010.01.020 · Cited by 218
Self-citation
High-Sensitivity C-Reactive Protein as Cardiovascular Risk Marker in Patients with Diabetes Mellitus
Pfützner, A., & Forst, T. M. (2006) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2006.8.28 · Cited by 221
C-reactive protein and angiographic coronary artery disease: independent and additive predictors of risk in subjects with angina
Zebrack, J. S., Muhlestein, J. B., Horne, B. D., & Anderson, J. L. (2002) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(01)01804-6 · Cited by 215
Justification for the Use of Statins in Primary Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER)—Can C-Reactive Protein Be Used to Target Statin Therapy in Primary Prevention?
Mora, S., & Ridker, P. M. (2005) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2005.11.014 · Cited by 219
Self-citation
NFkappaB is a Key Player in the Crosstalk between Inflammation and Cardiovascular Diseases
Fiordelisi, A., Iaccarino, G., Morisco, C., Coscioni, E., & Sorriento, D. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20071599 · Cited by 219
Usefulness of Admission Red Cell Distribution Width as a Predictor of Early Mortality in Patients With Acute Pulmonary Embolism
Zorlu, A., Bektaşoğlu, G., Güven, F. M. K., Doğan, Ö. T., Gücük, E., Ege, M. R., Altay, H., Çınar, Z., Tandoğan, İ., & Yılmaz, M. B. (2011) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2011.08.015 · Cited by 215
Atherosclerotic cardiovascular disease prevention in rheumatoid arthritis
Semb, A. G., Ikdahl, E., Wibetoe, G., Crowson, C. S., & Rollefstad, S. (2020) · Nature Reviews Rheumatology · doi:10.1038/s41584-020-0428-y · Cited by 221
Do atherosclerosis and type 2 diabetes share a common inflammatory basis?
Pradhan, A. (2002) · European Heart Journal · doi:10.1053/euhj.2001.3052 · Cited by 212
Low-grade inflammation as a risk factor for cardiovascular events and all-cause mortality in patients with type 2 diabetes
Sharif, S., Van der Graaf, Y., Cramer, M. J., Kapelle, L. J., de Borst, G. J., Visseren, F. L. J., Westerink, J., the SMART study group, van Petersen, R., Dinther, B. G. F., et al. (2021) · Cardiovascular Diabetology · doi:10.1186/s12933-021-01409-0 · Cited by 198
New Tools for Coronary Risk Assessment
Pearson, T. A. (2002) · Circulation · doi:10.1161/hc0702.103727 · Cited by 216
C-reactive protein comes of age
Verma, S., Szmitko, P. E., & Ridker, P. M. (2005) · Nature Clinical Practice Cardiovascular Medicine · doi:10.1038/ncpcardio0074 · Cited by 211
Self-citation
C-reactive protein: eighty years from discovery to emergence as a major risk marker for cardiovascular disease
Ridker, P. M. (2009) · Clinical Chemistry · doi:10.1373/clinchem.2008.119214 · Cited by 206
Self-citation
Stroke Prevention Therapy Beyond Antithrombotics: Unifying Mechanisms in Ischemic Stroke Pathogenesis and Implications for Therapy
Gorelick, P. B. (2002) · Stroke · doi:10.1161/hs0302.103657 · Cited by 211
Understanding and Managing Cancer Cachexia
Macdonald, N., Easson, A. M., Mazurak, V. C., Dunn, G. P., & Baracos, V. E. (2003) · Journal of the American College of Surgeons · doi:10.1016/s1072-7515(03)00382-x · Cited by 209
Angiotensin II Receptor Blocker Valsartan Suppresses Reactive Oxygen Species Generation in Leukocytes, Nuclear Factor-κB, in Mononuclear Cells of Normal Subjects: Evidence of an Antiinflammatory Action
Dandona, P., Kumar, V., Aljada, A., Ghanim, H., Syed, T., Hofmayer, D., Mohanty, P., Tripathy, D., & Garg, R. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-021836 · Cited by 210
C-reactive protein in rheumatology: biology and genetics
Rhodes, B., Fürnrohr, B. G., & Vyse, T. J. (2011) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2011.37 · Cited by 206
Traditional and emerging cardiovascular risk factors in end-stage renal disease
Zoccali, C., Mallamaci, F., & Tripepi, G. L. (2003) · Kidney International · doi:10.1046/j.1523-1755.63.s85.25.x · Cited by 200
Relation of Inflammation and Benefit of Statins After Percutaneous Coronary Interventions
Chan, A. W., Bhatt, D. L., Chew, D. P., Reginelli, J. P., Schneider, J. P., Topol, E. J., & Ellis, S. G. (2003) · Circulation · doi:10.1161/01.cir.0000060541.18923.e9 · Cited by 207
Inflammation and Atherothrombosis
Libby, P., & Ridker, P. M. (2006) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2006.08.011 · Cited by 204
Self-citation
Lifestyle-only intervention attenuates the inflammatory state associated with obesity: A randomized controlled study in adolescents
Balagopal, P., George, D. E., Patton, N., YARANDI, H. N., Roberts, W. L., Bayne, E., & Gidding, S. S. (2005) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2004.11.033 · Cited by 204
Statins and Stroke
Endres, M. (2005) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/sj.jcbfm.9600116 · Cited by 205
Beyond the Laboratory
Halcox, J., & Deanfield, J. E. (2004) · Circulation · doi:10.1161/01.cir.0000129500.29229.92 · Cited by 200
Statins for heart failure: at the crossroads between cholesterol reduction and pleiotropism?
von Haehling, S., & Anker, S. D. (2004) · Heart · doi:10.1136/hrt.2004.042515 · Cited by 201
Exercise Decreases Plasma Total Homocysteine in Overweight Young Women with Polycystic Ovary Syndrome
Randeva, H. S., Lewandowski, K. C., Drzewoski, J., Brooke-Wavell, K. S. F., O’Callaghan, C. J., Czupryniak, L., Hillhouse, E. W., & Prelević, G. M. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2001-012056 · Cited by 199
An Update on the Role of Markers of Inflammation in Atherosclerosis
Corrado, E., Rizzo, M., Coppola, G., Fattouch, K., Novo, G., Marturana, I., Ferrara, F., & Novo, S. (2010) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.2600 · Cited by 195
Effect of Pravastatin on Rate of Kidney Function Loss in People With or at Risk for Coronary Disease
Tonelli, M. A., Isles, C., Craven, T. E., Tonkin, A., Pfeffer, M. A., Shepherd, J., Sacks, F. M., Furberg, C. D., Cobbe, S. M., Simes, J. R., et al. (2005) · Circulation · doi:10.1161/circulationaha.104.517565 · Cited by 190
Interleukin-18-induced Human Coronary Artery Smooth Muscle Cell Migration Is Dependent on NF-κB- and AP-1-mediated Matrix Metalloproteinase-9 Expression and Is Inhibited by Atorvastatin
Chandrasekar, B., Mummidi, S., Mahimainathan, L., Patel, D. N., Bailey, S. R., Imam, S. Z., Greene, W. C., & Valente, A. J. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m600200200 · Cited by 197
Low-Dose Colchicine for Secondary Prevention of Coronary Artery Disease
Nelson, K. A., Fuster, V., & Ridker, P. M. (2023) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2023.05.055 · Cited by 211
Self-citation
Atorvastatin reduces proinflammatory markers in hypercholesterolemic patients
Ascer, E., Bertolami, M. C., Venturinelli, M. L., Buccheri, V., Souza, J. A., Nicolau, J. C., Ramires, J. A. F., & Junior, C. V. S. (2004) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2004.07.003 · Cited by 194
Inflammation and Cardiovascular Disease: 2025 ACC Scientific Statement
Mensah, G. A., Arnold, N., Prabhu, S. D., Ridker, P. M., & Welty, F. K. (2025) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2025.08.047 · Cited by 231
Self-citation
Inflammation and Atherosclerosis
Jialal, I., & Devaraj, S. (2001) · Pathology Patterns Reviews · doi:10.1309/j63v-5lth-wyfc-vdr5 · Cited by 195
Innate and adaptive immunity in atherosclerosis
Packard, R. R. S., Lichtman, A. H., & Libby, P. (2009) · Seminars in Immunopathology · doi:10.1007/s00281-009-0153-8 · Cited by 191
Circulating soluble adhesion molecules ICAM-1 and VCAM-1 and incident coronary heart disease: The PRIME Study
Luc, G., Arveiler, D., Evans, A., Amouyel, P., Ferrières, J., Bard, J., Elkhalil, L., Fruchart, J., & Ducimetière, P. (2003) · Atherosclerosis · doi:10.1016/s0021-9150(03)00280-6 · Cited by 193
Reduced arterial elasticity in rheumatoid arthritis and the relationship to vascular disease risk factors and inflammation
Wong, M., Toh, L., Wilson, A., Rowley, K., Karschimkus, C. S., Prior, D., Romas, E., Clemens, L., Dragicevic, G., Harianto, H., et al. (2003) · Arthritis & Rheumatism · doi:10.1002/art.10748 · Cited by 189

Authors: Ridker, P. M., Rifai, N., Clearfield, M., Downs, J. R., Weis, S. E., Miles, J. S., & Gotto, A. M.
Affiliations: Brigham and Women's Hospital (US)
University of North Texas Health Science Center (US)
Wilford Hall Ambulatory Surgical Center (US)
ORCID: Ridker, Paul M.
Rifai, Nader
Weis, Stephen E.
Gotto, Antonio M.
Venue: New England Journal of Medicine
Publisher: Massachusetts Medical Society
Published: 2001-06-28
Volume: 344
Issue: 26
Pages: 1959-1965
ISSN: 0028-4793 (ISSN-L)
1533-4406
DOI: 10.1056/nejm200106283442601
OpenAlex: W2316243284
Cited by: 1,557
References: 27
Citations by year: 2026: 12 · 2025: 19 · 2024: 16 · 2023: 29 · 2022: 34 · 2021: 30 · 2020: 35 · 2019: 38 · 2018: 29 · 2017: 25 · 2016: 39 · 2015: 41 · 2014: 39 · 2013: 43 · 2012: 52
FWCI: 158.00
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: New England Journal of Medicine (publishedVersion)
PubMed (publishedVersion)
Funders: Doris Duke Charitable Foundation
American Heart Association
Fondation Leducq
National Heart, Lung, and Blood Institute (R01HL058755, HL-58755)
Topics: Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Lipids, and Metabolism
Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Acute Myocardial Infarction Research
Keywords: C-reactive protein, statin therapy, lovastatin, primary prevention, acute coronary events, cardiovascular risk stratification, TC/HDL-C ratio, hyperlipidemia, inflammation, number needed to treat
MeSH terms: Acute Disease, Anticholesteremic Agents, C-Reactive Protein, Cholesterol, Coronary Disease, Double-Blind Method, Follow-Up Studies, Humans, Cholesterol, HDL, Lovastatin, Primary Prevention, Risk, Risk Factors, Proportional Hazards Models, Hydroxymethylglutaryl-CoA Reductase Inhibitors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Measurement of C-Reactive Protein for the Targeting of Statin Therapy in the Primary Prevention of Acute Coronary Events

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks